ClearPoint Neuro, Inc. (CLPT) Cash Flow Statement

The gap between net income and operating cash flow is largely driven by stock-based compensation, a non-cash expense that reduces reported losses but represents real economic dilution to shareholders. However, the fact that operating cash flow remains negative across all periods suggests that the company's fundamental cash generation from operations is insufficient to cover its cash operating costs, a concerning trend for a growth-stage business.

The trajectory of free cash flow is deeply concerning, as the company is not only failing to generate cash but is consuming it at an accelerating rate. This suggests that revenue growth is not translating into operational efficiency or scale benefits, and the negative operating leverage identified in the income statement is directly impacting cash generation.

The low capital expenditure requirement suggests that ClearPoint Neuro's business model does not rely on heavy manufacturing assets, which is typical for a medical device company that may outsource production. However, the minimal capex also means that the company's negative free cash flow is almost entirely driven by operating losses rather than investment in growth assets, reinforcing the urgency of addressing the core operational cash drain.

The significant working capital swings, particularly the large cash drain in 2025Q4, suggest that the company's ability to manage its operating cycle is inconsistent. This volatility complicates cash flow forecasting and indicates that working capital management may be a secondary challenge on top of the primary issue of operational cash burn.